Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)(I-FIRST) | unknown | Phase 2 | 80 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition(ERRITI) | unknown | Phase 2 | 70 | University Hospital, EssenOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05659186 | PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05299437 | Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry(131THEROPT124) | unknown | Phase 2 | 50 | Carlo ChiesaOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04952493 | Anlotinib or Penpulimab in Combination With RAI for DTC | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04309136 | Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer | unknown | Phase 2 | 13 | Fudan UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy | unknown | Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04524884 | Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02839655 | Prospective Study Assessing Thyroidectomy Using Robot(EVATAR) | unknown | Phase 2 | 17 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03387943 | PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 3, 2018 | clinicaltrials |
| NCT03300765 | Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer | unknown | Phase 2 | 20 | Xiayun He, MDOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02418247 | Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer | unknown | Phase 2 / Phase 3 | 556 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01830504 | A Multicenter Phase II Pilot Open Label(BKM120) | unknown | Phase 2 | 47 | Hospices Civils de LyonOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01739634 | The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | unknown | Phase 1 / Phase 2 | 10 | Salient Pharmaceuticals IncorporatedINDUSTRY | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00786552 | Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer(Panthera) | unknown | Phase 2 | 47 | University Hospital Schleswig-HolsteinOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00948337 | A Study With Health Educational Material on Health Promotion in Cancer Survivors | unknown | Phase 2 | 326 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 26, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Apr 12, 2024source: clinicaltrials